Showing results (221-230 of 261) with videos related to
Sort By:
Pageof 27
Gastroenterology|February 20, 2013
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinomaDarjus Felix Tschaharganeh, Xin Chen, Philipp Latzko, et al.Cancer Research|September 12, 2025
Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular CarcinomaGuofei Cui, Yi Zhou, Weiting Liao, et al.European Surgery : ACA : Acta Chirurgica Austriaca|December 19, 2018
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expectedSonja Kappel-Latif, Johannes Zacherl, Michael Hejna, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2023
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET InhibitionRichard Riedel, Jana Fassunke, Andreas H Scheel, et al.Genes, Chromosomes & Cancer|October 26, 2019
Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assaysNicole Pfarr, Martina Kirchner, Ulrich Lehmann, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 3, 2024
PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine NeoplasmsAlbert Grass, Atsuko Kasajima, Sebastian Foersch, et al.Gastroenterology|April 30, 2022
β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in CholangiocarcinomaYi Zhang, Hongwei Xu, Guofei Cui, et al.American Journal of Hematology|August 7, 2023
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMTLisa Pleyer, Marc Vaisband, Manuel Drost, et al.American Journal of Hematology|February 23, 2023
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasmsDaniel Ivanov, Jelena D Milosevic Feenstra, Irina Sadovnik, et al.Journal of Hepatology|April 22, 2021
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targetedAdrián Vallejo, Oihane Erice, Rodrigo Entrialgo-Cadierno, et al.Pageof 27